Search Medical Condition
Please enter condition
Please choose location from dropdown

Kanagawa, Yokohama, Japan Clinical Trials

A listing of Kanagawa, Yokohama, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (203) clinical trials

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

This trial has two sequentially enrolling parts with different objectives. The primary objectives of this trial are to prove the concept of clinical activity of BI 655130 in patients with moderate-to-severely active ulcerative colitis who have failed previous biologic treatments and to identify efficacious and safe dose regimens in Part ...

Phase

8.5 miles

Learn More »

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.

Phase

8.5 miles

Learn More »

A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065

The purpose of this study is to evaluate safety and efficacy of risankizumab in subjects with ulcerative colitis (UC) in subjects who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC. This study consists of three sub-studies: Substudy 1 is a 52-week, randomized, double-blind, ...

Phase

8.5 miles

Learn More »

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

JNJ-53718678 is an investigational respiratory syncytial virus (RSV) specific fusion inhibitor and is under development for the treatment of RSV infection, which results in an upper and/or lower respiratory tract illness. The primary hypothesis of this study is that JNJ-53718678 has antiviral activity against RSV (that is, results in a ...

Phase

8.74 miles

Learn More »

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will get semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is ...

Phase

8.97 miles

Learn More »

Study To Evaluate the Efficacy Safety and Tolerability of E2027 in Participants With Dementia With Lewy Bodies

This study will be conducted to compare E2027 to placebo on the cognitive endpoint of Montreal Cognitive Assessment (MoCA) and the global clinical endpoint of Clinician's Interview Based Impression of Change Plus (CIBIC-Plus) Caregiver Input in participants with dementia with Lewy bodies after 12 weeks of treatment.

Phase

9.06 miles

Learn More »

Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households

Otherwise healthy index patients (IP) are randomized to either baloxavir marboxil or placebo if their influenza symptoms onset was within 48 hours of screen. Their households are enrolled within 24 hours of randomization if at least 2 household contacts (HHC) have not received influenza vaccine within 6 months of screening ...

Phase

9.16 miles

Learn More »

Long-Term Retention of Gadolinium in Bone

The purpose of the study is to further investigate the safety of six different commercially used Gadolinium-containing contrast agents. In order to get a better view of internal organs such as the brain, joints and other body regions contrast agents containing Gadolinium are often administered during magnetic resonance imaging. Gadolinium-containing ...

Phase N/A

9.2 miles

Learn More »

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

The objective of this study is to evaluate the efficacy and safety of Upadacitinib compared to placebo in inducing clinical remission (per Adapted Mayo score) in participants with moderately to severely active ulcerative colitis (UC).

Phase

9.23 miles

Learn More »

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43)

Following a lead-in period during which all participants receive a single 3-week cycle of carboplatin/paclitaxel, participants will be randomly assigned in to one of three treatment arms Pembrolizumab+Olaparib, Pembrolizumab+Placebo for Olaparib, or Placebo for Pembrolizumab+Placebo for Olaparib. At Investigator's discretion and prior to participant randomization, one of the following carboplatin/paclitaxel ...

Phase

9.24 miles

Learn More »